Introduction: practical basic safety panel screening uses functional assays, kinase/transporter profiling, and State-of-the-art visualization to detect off-target liabilities early, improving preclinical safety assessments. Just previous 7 days, a late-phase drug prospect unexpectedly showed adverse results that hadn’t appeared in before assays,